Fabry disease

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Fabry disease
Synonyms	Anderson-Fabry disease, alpha-galactosidase A deficiency
Pronounce
Specialty	Medical genetics
Symptoms	Pain, angiokeratoma, hypohidrosis, corneal opacity, tinnitus, hearing loss, kidney failure, heart disease
Complications	N/A
Onset	Childhood to adulthood
Duration	Lifelong
Types	N/A
Causes	Mutations in the GLA gene
Risks	Family history
Diagnosis	Genetic testing, enzyme assay
Differential diagnosis	Rheumatic fever, rheumatoid arthritis, multiple sclerosis
Prevention	N/A
Treatment	Enzyme replacement therapy, pain management, kidney transplantation
Medication	Agalsidase alfa, agalsidase beta, migalastat
Prognosis	Variable, depends on organ involvement and treatment
Frequency	1 in 40,000 to 1 in 117,000 males
Deaths

Fabry Disease

Fabry disease is a rare genetic disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells. It is an X-linked recessive disorder caused by mutations in the GLA gene, which leads to a deficiency of the enzyme alpha-galactosidase A.

Pathophysiology

Fabry disease is characterized by the accumulation of glycosphingolipids in the lysosomes of various cell types. The deficiency of alpha-galactosidase A enzyme activity results in the progressive deposition of globotriaosylceramide in the vascular endothelium, smooth muscle cells, and other tissues, leading to multi-systemic manifestations.

Clinical Manifestations

The symptoms of Fabry disease can vary widely among affected individuals, but common manifestations include:

• Angiokeratomas: Small, dark red spots on the skin, often found in the "bathing trunk" area.
• Acroparesthesia: Episodes of pain and burning sensations in the hands and feet.
• Corneal verticillata: Whorled patterns on the cornea, detectable by an eye examination.
• Renal impairment: Progressive kidney damage leading to chronic kidney disease.
• Cardiac involvement: Hypertrophic cardiomyopathy, arrhythmias, and heart failure.
• Cerebrovascular disease: Increased risk of stroke and transient ischemic attacks.

Diagnosis

Diagnosis of Fabry disease is typically confirmed through:

• Enzyme assay: Measurement of alpha-galactosidase A activity in blood or skin fibroblasts.
• Genetic testing: Identification of mutations in the GLA gene.
• Biopsy: Histological examination of affected tissues may show characteristic lipid deposits.

Treatment

The management of Fabry disease includes:

• Enzyme replacement therapy (ERT): Intravenous administration of recombinant alpha-galactosidase A to reduce globotriaosylceramide accumulation.
• Chaperone therapy: Use of pharmacological chaperones to stabilize the mutant enzyme and enhance its activity.
• Symptomatic treatment: Pain management, renal protection, and cardiovascular care.
• Gene therapy: An emerging approach aimed at correcting the underlying genetic defect.

Prognosis

The prognosis of Fabry disease varies depending on the severity of organ involvement and the effectiveness of treatment. Early diagnosis and initiation of therapy can improve outcomes and quality of life.

Epidemiology

Fabry disease is estimated to affect approximately 1 in 40,000 to 1 in 117,000 live births. It is more common in males due to its X-linked inheritance pattern, but females can also be affected, often with milder symptoms.

Images

• 
  Fabry disease
• 
  Fabry disease

See Also

• Lysosomal storage disease
• X-linked genetic disorders
• Hypertrophic cardiomyopathy